Merck immunotherapy fails to improve survival in head and neck cancerWHTC(Reuters) – Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the… Continue reading
Genome editing with CRISPR-Cas9 prevents angiogenesis of the retinaMedical XpressCRISPR-associated protein Cas9 (white) from Staphylococcus aureus based on Protein Database ID 5AXW. Credit: Thomas Splettstoesser (Wikipedia, CC BY-SA 4.0). A research te… Continue reading
HealthlineNew Gene Therapy Produces Hope for a New Era in Cancer …HealthlineGene-altering therapy on the cusp of FDA approval may soon be treating children with advanced leukemia.More CAR-T Therapies Sought | GenomeWebGenomeWeball 4 news articles&nbs… Continue reading
HealthlineNew Gene Therapy Produces Hope for a New Era in Cancer …HealthlineGene-altering therapy on the cusp of FDA approval may soon be treating children with advanced leukemia.More CAR-T Therapies Sought | GenomeWebGenomeWeball 4 news articles&nbs… Continue reading
Cellectis Granted Patent for CRISPR Use in T-CellsMarkets InsiderEP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells. The patent will be issued on August 2, 2017. This therapeutic-f… Continue reading
Cellectis Granted Patent for CRISPR Use in T-CellsMarkets InsiderEP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells. The patent will be issued on August 2, 2017. This therapeutic-f… Continue reading
Genetic Engineering & Biotechnology News (blog) |
Cellectis Granted T Cell CRISPR Patent in Europe
Genetic Engineering & Biotechnology News (blog) The bitter patent feud over CRISPR, a gene-editing tool with unprecedented potential, continues in the United States. Meanwhile, French biotech Cellectis is staking a claim to the technology in Europe. Cellectis announced that the European Patent … Cellectis Granted Patent for CRISPR Use in T-CellsBusiness Wire (press release) |
Ars Technica |
Dozens of US clinics sell unproven stem cell therapies for heart failure
Reuters (Reuters Health) – Stem cell therapy isn’t approved to treat heart failure in the U.S., but dozens of clinics nationwide advertise the treatments anyway, often charging thousands of dollars for procedures that may not be safe or effective, a new study … The curious case of ClinicalTrials.gov, where dubious stem cell therapies seem legitArs Technica Stem Cell Clinics Are Advertising Their Treatments As Clinical Trials. They’re NotForbes ‘Stem cell centers’ often deliver therapy for HF without preevaluations, follow-upHealio MinnPost –PR Newswire (press release) –MedPage Today all 12 news articles » |